Axogen Appoints Dr. Steven J. Williams as New CMO
Ticker: AXGN · Form: 8-K · Filed: Aug 9, 2024 · CIK: 805928
| Field | Detail |
|---|---|
| Company | Axogen, Inc. (AXGN) |
| Form Type | 8-K |
| Filed Date | Aug 9, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.01, $765,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
Related Tickers: INSP
TL;DR
Axogen names new CMO, Dr. Steven J. Williams, from Inspire Medical.
AI Summary
Axogen, Inc. announced on August 8, 2024, the appointment of Dr. Steven J. Williams as Chief Medical Officer. Dr. Williams previously served as Chief Medical Officer at Inspire Medical Systems, Inc. and has extensive experience in medical device innovation and clinical development.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for Axogen's strategic direction in developing and commercializing innovative nerve repair solutions.
Risk Assessment
Risk Level: low — This filing is an 8-K reporting a routine executive appointment, not a material financial event.
Key Players & Entities
- Axogen, Inc. (company) — Registrant
- Dr. Steven J. Williams (person) — Newly appointed Chief Medical Officer
- Inspire Medical Systems, Inc. (company) — Previous employer of Dr. Williams
FAQ
What is the effective date of Dr. Steven J. Williams' appointment as Chief Medical Officer?
The filing does not explicitly state an effective date for the appointment, but it was reported on August 8, 2024.
What was Dr. Steven J. Williams' previous role before joining Axogen?
Dr. Steven J. Williams previously served as the Chief Medical Officer at Inspire Medical Systems, Inc.
What is Axogen, Inc.'s state of incorporation?
Axogen, Inc. is incorporated in Minnesota.
What is Axogen, Inc.'s IRS Employer Identification Number?
Axogen, Inc.'s IRS Employer Identification Number is 41-1301878.
What is the SIC code for Axogen, Inc.?
The Standard Industrial Classification (SIC) code for Axogen, Inc. is 3845, which corresponds to ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS.
Filing Stats: 1,415 words · 6 min read · ~5 pages · Grade level 11.3 · Accepted 2024-08-09 16:05:37
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value AXGN The Nasdaq Stock Mar
- $765,000 — ement, Mr. Dale's annual base salary is $765,000 and he is eligible to participate in th
Filing Documents
- d831362d8k.htm (8-K) — 35KB
- d831362dex101.htm (EX-10.1) — 132KB
- d831362dex102.htm (EX-10.2) — 75KB
- d831362dex103.htm (EX-10.3) — 74KB
- d831362dex991.htm (EX-99.1) — 14KB
- g831362g0808225256062.jpg (GRAPHIC) — 5KB
- 0001193125-24-197821.txt ( ) — 545KB
- axgn-20240808.xsd (EX-101.SCH) — 3KB
- axgn-20240808_lab.xml (EX-101.LAB) — 18KB
- axgn-20240808_pre.xml (EX-101.PRE) — 11KB
- d831362d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Employment Agreement, dated August 9, 2024 10.2* Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August 9, 2024, by and between the Company and Michael Dale (TSR) 10.3* Axogen, Inc. Performance-Based Restricted Stock Units Notice Inducement Award Agreement, effective as of August 9, 2024, by and between the Company and Michael Dale (Performance) 99.1 Axogen Inc. Press Release, dated August 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Management contract or compensatory plan arrangement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AXOGEN, INC. Dated: August 9, 2024 By: /s/ Marc Began Marc Began Executive Vice President, General Counsel and Chief Compliance Officer